| IntroductionAngiogenesis is essential for tumor generation . Vascular endo-thelial cell growth factor ( VEGF) is an important regulating factor for angiogenesis. The importance of VEGF in solid tumors (ST) has been established and further the serum VEGF levels in some patients with ST can reflect the burdens of tumor cells, the progression of the disease and so on.Resent researches have provided the evidence of angiogenesis in bone marrow or infiltrating tissues of hematopoetic malignances. Human hematopoitic tumor cells express and secret VEGF protein. It is possible that VEGF may play a role in the growth of hematopoitic neoplasms through an autocrine or a paracrine mechanism. On the basis of the above background , this test evaluated the serum VEGF levels of patients with hematopoitic tumors, including acute leukemia(AL) , non -Hodgkin's lymphoma(NHL) , multiple myeloid ( MM) and performed control study with healthy groups in order to explore whether or not the serum VEGF levels have clinical significances reflecting the burdens of tumor cells . the activity of tumors and so on.Patients and MethodsPatients and control subjectsPatients diagnosed with NHL were chosed. There were 12 males and 2 females with a mean age of 52. 44 years. Patients were stagedaccording to the Ann Arbor staging system and distributed as follows: 1 stage I , 3 stage II , 5 stage III, 5 stage IV . 6 patients had B sym-toms . Among 6 patients who were followed for receiving chemotherapy periodically, 3 patients had good response while the other 3 bad rese-ponse.There were 8 patients with MM , including 6 men and 2 women with their average age 54. 8 years.16 patients with primary or secondary acute leukemia entered this test, 7 males and 9 females with average age 40.6 years. According to the FAB typing system, 10 ANLL type, 1 M1 type,2M2 type, 2 M3 type. 2 M4 type, 4 M5 type; 6 ALL type: 1 L1 type, 4 L2 type, 1 L3 type. S leukemia patients in complete response(CR) were chosed, including 4 men and 4 women with mean age 38. 88 years. 8 patients with non-hemotoiogical cancers, 5 males and 3 females, average age 50.75years.Serum samples from 8 healthy blood donors, including 5 men and 3 women whose average age were 40. 88 years were got.Venous Slood samples. Pheripheral venous blood samples were collected in sterile test tubes before starting therapy, within 2 hours centifuged at 2000g for 10 minutes and then stored at -20 C.Serum VEGF concentrations were determined by using a quantita-tive sandwich enzyme immunoassay technique(ELISA).Results1. The serum concentrations of VEGF in NHL patients. The difference of serum levels of VEGF is not found between NHL patients(14 cases) and 8 normal control group(8 cases) (p>0.05). The correlation of serum of VEGF with both classification and severity of B group were not found in the NHL patients( (p>0.05). However, the serum LDH level is highly significantly correlated with VEGF level in the NHL patients with VEGF level higher than the median(medien 228.5 pg/ml) (r=0.812, p<0.05).Among these 14 NHL patients, 6 patients had chemotherapy treatment, 3 patients had good response to the chemotherapy treatment and the other 3 patients did not response well. Before the chemotherapy treatment, the VEGF level is significantly lower in the patients with good chemotherapy response than in patients with bad response(p<0. 01).2. The serum level of VEGF in MM patients.The serum level of VEGF of 8 MM patients was significantly higher compared to the normal control group(p<0.01), the group of patients with non - hematopoitic tumors( p<0.01), the NHL patients(p <0.05). The correlations between VEGF and 2-microglobin, VEGF and percentage of bone marrow myeloid cells are not shown in MM patients.3. The serum VEGF level of AL patients.The serum level of VEGF of primary or secondary AL patients are significantly lower than that of both healthy control and CR groups ( p <0. 05 for all the comparisons). The serum VEGF levels of ANLL patients were higher... |
PDF Full Text Request